2. Search Result
Search Result
Results for "

PCSK9-IN-9

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

3

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148673
    AZD0780

    PCSK9-IN-12

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    AZD0780 (PCSK9-IN-12) is an orall active PCSK9 inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of <200 nM. AZD0780 binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. AZD0780 inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. PCSK9-IN-12 can be used for the research of hypercholesterolemia .
    AZD0780
  • HY-P99552
    Tafolecimab

    IBI-306

    		 PCSK9 Cardiovascular Disease
    Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
    Tafolecimab
  • HY-152221
    PCSK9-IN-10

    		PCSK9 Cardiovascular Disease Metabolic Disease
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .
    PCSK9-IN-10
  • HY-N10702
    PCSK9-IN-9

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-9 is an isocoumarins of natural origin. PCSK9-IN-9 can inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), IDOL, and SREBP2 mRNA expression. PCSK9-IN-9 inhibits PCSK9 with an IC50 value of 11.9 μM .
    PCSK9-IN-9
  • HY-149310
    Dim16

    		Ser/Thr Protease Metabolic Disease
    Dim16 is a dual PCSK9/HMG-CoAR inhibitor, with an IC50 value of 19 nM for PCSK9. Dim16 inhibits PCSK9-LDLR binding with an IC50 value of 0.8 nM. Dim16 increases LDL uptake in HepG2 cells .
    Dim16
  • HY-160036
    PCSK9-IN-22

    		PCSK9 Metabolic Disease
    PCSK9-IN-22 (compound 29) is an orally active inhibitor of PCSK9. PCSK9-IN-22 inhibits the interaction of the protein with LDLR in vivo .
    PCSK9-IN-22
  • HY-132897
    PCSK9-IN-2

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-2 is a novel small molecule inhibitor of PCSK9-LDLR protein–protein interaction (PPI) with an IC50 value of 7.57 μM.
    PCSK9-IN-2
  • HY-P99696
    Lerodalcibep

    LIB003

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
    Lerodalcibep
  • HY-163141
    PCSK9-IN-24

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-24 (Compound OY3) is a compound that targets PCSK9. PCSK9-IN-24 reduces PCSK9 levels and increases LDL uptake and may be used in atherosclerosis research .
    PCSK9-IN-24
  • HY-P11071
    PCSK9 Inhibitor, EGF-A

    		PCSK9 Cardiovascular Disease
    PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .
    PCSK9 Inhibitor, EGF-A
  • HY-P990485
    Anti-PCSK9 Antibody

    		PCSK9 Inflammation/Immunology
    Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-PCSK9 Antibody
  • HY-125916
    Pseurotin A

    		Endogenous Metabolite Cancer
    Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50 = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .
    Pseurotin A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: